N/A N=90

Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance

Cardiac Surgery

Bottom Line

View on ClinicalTrials.gov: NCT03395886 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2019

Primary outcome: Primary: Number of Participants With NIV Failure — 10; 8 Participants — p=0.831

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Remifentanil (Drug); Dexmedetomidine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Shanghai Zhongshan Hospital
Primary completion: Mar 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With NIV Failure	10; 8	0.831
SECONDARY Number of Participants With NIV Mitigation	44; 31	0.800

Summary

The aim of this study is to compare the sedation effects between remifentanil and dexmedetomidine in post-cardiac surgical patients who developed noninvasive ventilation (NIV) intolerance.

Eligibility Criteria

Inclusion Criteria

adult patients
after cardiac surgery
receiving noninvasive ventilation
moderate to severe NIV intolerance (NIV intolerance score of 3 or 4)

Exclusion Criteria

difficult expectoration
pregnancy or breastfeeding
intensive care delirium screening checklist score more than 4
drug abuse history
known allergy to opiods
cardiogenic shock
malignant arrhythmias

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03395886). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.